# scPharmaceuticals Inc.

scPharmaceuticals Inc. is a company headquartered in Burlington, MA, United States.

## Company overview

- **Legal name:** scPharmaceuticals Inc.
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Burlington, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001604950

## About

scPharmaceuticals Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001604950, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2025-03-19, it reported annual revenue of USD 36,332,000; net income of USD -85,148,000; total assets of USD 107,519,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Revenue:** $36.3M (USD 36,332,000)
- **Net income:** -$85.1M (USD -85,148,000)
- **Total assets:** $107.5M (USD 107,519,000)
- **Cash and equivalents:** $75.7M (USD 75,655,000)
- **Operating cash flow:** -$70.5M (USD -70,538,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $13.6M (USD 13,593,000)
- **Net income:** -$54.8M (USD -54,810,000)
- **Total assets:** $94.5M (USD 94,479,000)
- **Cash and equivalents:** $46.8M (USD 46,814,000)
- **Operating cash flow:** -$59.2M (USD -59,244,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$36.8M (USD -36,838,000)
- **Total assets:** $124.2M (USD 124,195,000)
- **Cash and equivalents:** $71.1M (USD 71,061,000)
- **Operating cash flow:** -$34.6M (USD -34,577,000)

### FY2021 (period ended 2021-12-31)

- **Net income:** -$28.0M (USD -28,034,000)
- **Total assets:** $79.0M (USD 79,037,000)
- **Cash and equivalents:** $74.3M (USD 74,268,000)
- **Operating cash flow:** -$27.2M (USD -27,151,000)

## Recent SEC filings

- Form 8-K — filed 2025-10-07 — period 2025-10-07 — 8-K
- Form 8-K — filed 2025-09-24 — period 2025-09-23 — 8-K
- Form 8-K — filed 2025-08-25 — period 2025-08-24 — 8-K
- Form 8-K — filed 2025-08-25 — period 2025-08-20 — 8-K
- Form 10-Q — filed 2025-08-07 — period 2025-06-30 — 10-Q
- Form 8-K — filed 2025-08-07 — period 2025-08-07 — 8-K
- Form 8-K — filed 2025-06-09 — period 2025-06-03 — 8-K
- Form 10-Q — filed 2025-05-14 — period 2025-03-31 — 10-Q
- Form 8-K — filed 2025-05-14 — period 2025-05-14 — 8-K
- Form DEF 14A — filed 2025-04-21 — period 2025-06-03 — DEF 14A
- Form 10-K — filed 2025-03-19 — period 2024-12-31 — 10-K
- Form 8-K — filed 2025-03-19 — period 2025-03-19 — 8-K

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/scpharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology